| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
and Epidermal Growth Factor Receptor Messenger RNA in Neoplastic and Nonneoplastic Human Kidney Tissue
Laboratory of Urologic Oncology Research, Urology Service, Department of Surgery [J. H. M., W. D. W. H., W. R. F.], the DeWitt Wallace Research Laboratory [J. M.], Department of Pathology [C. C-C.], and the Laboratory of Receptor Biology [A. S. G.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021
Using Northern blot analysis, we have demonstrated that mRNA for transforming growth factor 
(TGF-) was expressed in five malignant kidney tissue specimens but was not detected in their autologous nonneoplastic homologues. In addition, the expression of epidermal growth factor (EGF) receptor mRNA in these malignant tissues was 2- to 3-fold greater than in nontransformed tissues. In two cases examined using immunohistochemistry, we were able to correlate the increased expression of the mRNA with an increase in protein expression. Since TGF- is known to bind to the EGF receptor, the finding of an increased expression of both TGF- and EGF receptor mRNA in kidney tumor tissue suggests that interaction between TGF- and the EGF receptor may play a role in promoting transformation and/or proliferation of kidney neoplasms, perhaps by an autocrine mechanism.
1 To whom requests for reprints should be addressed, at Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.
Received 6/ 7/88. Revised 2/16/89. Accepted 3/20/89.
This article has been cited by other articles:
|
|
 |
|
  A. Franovic, I. Robert, K. Smith, G. Kurban, A. Pause, L. Gunaratnam, and S. Lee Multiple Acquired Renal Carcinoma Tumor Capabilities Abolished upon Silencing of ADAM17 Cancer Res., August 15, 2006; 66(16): 8083 - 8090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Vieira Association between the Transforming Growth Factor Alpha Gene and Nonsyndromic Oral Clefts: A HuGE Review Am. J. Epidemiol., May 1, 2006; 163(9): 790 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. An and M. B. Rettig Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor kappa B Activity Mol. Cell. Biol., September 1, 2005; 25(17): 7546 - 7556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Y. Kim and W. G. Kaelin Role of VHL Gene Mutation in Human Cancer J. Clin. Oncol., December 15, 2004; 22(24): 4991 - 5004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Dawson, C. Guo, R. Zak, B. Dorsey, J. Smoot, J. Wong, and A. Hussain A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma Clin. Cancer Res., December 1, 2004; 10(23): 7812 - 7819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Gunaratnam, M. Morley, A. Franovic, N. de Paulsen, K. Mekhail, D. A. E. Parolin, E. Nakamura, I. A. J. Lorimer, and S. Lee Hypoxia Inducible Factor Activates the Transforming Growth Factor-{alpha}/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells J. Biol. Chem., November 7, 2003; 278(45): 44966 - 44974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Weber, M. Doucet, J. E. Price, C. Baker, S. J. Kim, and I. J. Fidler Blockade of Epidermal Growth Factor Receptor Signaling Leads to Inhibition of Renal Cell Carcinoma Growth in the Bone of Nude Mice Cancer Res., June 1, 2003; 63(11): 2940 - 2947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cai, J. I. Everitt, H. Kugo, J. Cook, E. Kleymenova, and C. L. Walker Polycystic Kidney Disease as a Result of Loss of the Tuberous Sclerosis 2 Tumor Suppressor Gene During Development Am. J. Pathol., February 1, 2003; 162(2): 457 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Haas, M. Smith, N. Lewis, L. Littman, G. Yeslow, I. D. Joshi, A. Murgo, J. Bradley, R. Gordon, H. Wang, et al. Weekly Bryostatin-1 in Metastatic Renal Cell Carcinoma: A Phase II Study Clin. Cancer Res., January 1, 2003; 9(1): 109 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Mcdorman and D. C. Wolf Use of the Spontaneous Tsc2 Knockout (Eker) Rat Model of Hereditary Renal Cell Carcinoma for the Study of Renal Carcinogens Toxicol Pathol, October 1, 2002; 30(6): 675 - 680. [Abstract] [PDF]
|
|
|
|
|
|
S. D. Mertins, T. G. Myers, M. Hollingshead, D. Dykes, E. Bodde, P. Tsai, C. A. Jefferis, R. Gupta, W. M. Linehan, M. Alley, et al. Screening for and Identification of Novel Agents Directed at Renal Cell Carcinoma Clin. Cancer Res., March 1, 2001; 7(3): 620 - 633. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. PANSKY, A. DE WEERTH, E. FASLER-KAN, J.-L. BOULAY, M. SCHULZ, S. KETTERER, C. SELCK, C. BEGLINGER, T. VON SCHRENCK, and P. HILDEBRAND Gastrin Releasing Peptide-Preferring Bombesin Receptors Mediate Growth of Human Renal Cell Carcinoma J. Am. Soc. Nephrol., August 1, 2000; 11(8): 1409 - 1418. [Abstract] [Full Text]
|
|
|
|
|
|
A. D. Perera, E. V. Kleymenova, and C. L. Walker Requirement for the von Hippel-Lindau Tumor Suppressor Gene for Functional Epidermal Growth Factor Receptor Blockade by Monoclonal Antibody C225 in Renal Cell Carcinoma Clin. Cancer Res., April 1, 2000; 6(4): 1518 - 1523. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. J. Motzer, N. H. Bander, and D. M. Nanus Renal-Cell Carcinoma N. Engl. J. Med., September 19, 1996; 335(12): 865 - 875. [Full Text] [PDF]
|
|
|
|
 |
|
 N. de Paulsen, A. Brychzy, M.-C. Fournier, R. D. Klausner, J. R. Gnarra, A. Pause, and S. Lee Role of transforming growth factor-alpha in von Hippel- Lindau (VHL)-/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis PNAS, February 13, 2001; 98(4): 1387 - 1392. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
